Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: Pharmacokinetic evaluation and dose recommendation

Critical Care

Volumn 10, Issue 1, 2006, Pages

  Mariat, Christophe ^a   Venet, Christophe ^b   Jehl, François ^c   Mwewa, Sandrine ^d   Lazarevic, Vesna ^d   Diconne, Eric ^b   Fonsale, Nathalie ^b   Carricajo, Anne ^b   Guyomarc'h, Stéphane ^b   Vermesch, Régine ^b   Aubert, Gérald ^b   Bidault, Roselyne ^d   Bertrand, Jean Claude ^b   Zeni, Fabrice ^b  

^a HÔPITAL NORD   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRITICALLY ILL PATIENT; DIALYSATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULTRAFILTRATION; ACUTE KIDNEY FAILURE; BLOOD; CRITICAL ILLNESS; DRUG ADMINISTRATION; EVALUATION; HEMODIAFILTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PRACTICE GUIDELINE; STANDARD;

ADULT; AGED; CEFTAZIDIME; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MIDDLE AGED; PRACTICE GUIDELINES; PROSPECTIVE STUDIES;

EID: 33748437344     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc3993     Document Type: Article

References (32)

1. Mouton JW Hollander JG Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model Antimicrob Agents Chemother 1994 38 931-936 188129 8067772
2. Craig WA Does the dose matter? Clin Infect Dis 2001 33 Suppl 3 S233-S237 10.1086/321854 11524724
3. Craig WA Ebert SC Continuous infusion of β-lactam antibiotics Antimicrob Agents Chemother 1992 36 2577-2583 245510 1482127
4. Mouton JW Vinks AA Is continuous infusion of β-lactam antibiotics worthwile? Efficacy and pharmacokinetic considerations J Antimicrob Chemother 1996 38 5-15 8858451
5. Angus BJ Smith MD Suputtamongkol Y Mattie H Walsh AL Wuthiekanun V Chaowagul W White NJ Pharmacokinetic-pharmacodynamic evaluation of cefatzidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis Br J Clin Pharmacol 2000 50 184-191 10.1046/ j.1365-2125.2000.00179.x 10930972
6. Boselli E Breilh D Rimmele T Poupelin JC Saux MC Chassard D Allaouchiche B Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia Intensive Care Med 2004 30 989-991 10.1007/s00134-004-2171-2 14985960
7. Buijk SLCE Gyssens IC Mouton JW Van Vliet A Verbrugh HA Bruining HA Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections J Antimicrob Chemother 2002 49 121-128 10.1093/jac/49.1.121 11751775
8. Dalle JH Gnansounou M Husson MO Lambilliotte A Mazingue F Nelken B Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer J Pediatr Hematol Oncol 2002 24 714-716 10.1097/00043426-200212000-00006 12468910
9. Egerer G Goldschmidt H Hensel M Harter C Schneeweiss A Ehrhard I Bastert G Ho AD Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation Bone Marrow Transplant 2002 30 427-431 10.1038/sj.bmt.1703660 12368954
10. Hanes SD Wood GC Herring V Croce MA Fabian TC Pritchard E Boucher BA Intermittent and continuous ceftazidime infusion for critically ill trauma patients Am J Surg 2000 179 436-440 10.1016/S0002-9610(00)00388-3 11004326
11. Nicolau DP McNabb JC Lacy MK Quintiliani R Nightingale CH Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia Int J Antimicrob Agents 2001 17 497-504 10.1016/S0924-8579(01)00329-6 11397621
12. Vinks AATMM Touw DJ Heijerman HGM Danhof M de Leede GPJ Bakker W Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home Ther Drug Monit 1994 16 341-348 7974622
13. Harding SM Ayrton J Thornton JE Munro AJ Hogg MIJ Pharmacokinetics of ceftazidime in normal subjects J Antimicrob Chemother 1981 261
14. Leroy A Leguy F Borsa F Spencer GR Fillastre JP Humbert G Pharmacokinetics of ceftazidime in normal and uremic subjects Antimicrob Agents Chemother 1984 25 638-642 185604 6375562
15. Van Dalen R Vree TB Baars AM Termond E Dosage adjustment for ceftazidime in patients with impaired renal function Eur J Clin Pharmacol 1986 30 597-605 10.1007/BF00542421 3530782
16. Walstad RA Dahl K Hellum KB Thurmann-Nielsen E The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent furosemide therapy Eur J Clin Pharmacol 1988 35 273-279 10.1007/ BF00558265 3053209
17. Joos B Schmidli M Keusch G Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration Nephrol Dial Transplant 1996 11 1582-1585 8856215
18. Matzke GR Frye F Joy MS Palevsky PM Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis Antimicrob Agents Chemother 2000 44 1639-1644 89925 10817721 10.1128/AAC.44.6.1639-1644.2000
19. Nikolaidis P Tourkantonis A Effect of hemodialysis on ceftazidime pharmacokinetics Clin Nephrol 1985 24 142-146 3899438
20. Vincent HH Vos MC Akcahuseyin E Goessens WHF van Duyl WA Schalekamp MADH Drug clearance by continuous haemodiafiltration Blood Purif 1993 11 99-107 8274246
21. Traunmüller F Schenk P Mittermeyer C Thalhammer-Scherrer R Ratheiser K Thalhammer F Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients J Antimicrob Chemother 2002 49 129-134 10.1093/jac/49.1.129 11751776
22. Sato T Okamoto K Kitaura M Kukita I Kikuta K Hamaguchi M The pharmacokinetics of ceftazidime during hemodiafiltration in critically ill patients Artif Organs 1999 23 143-145 10.1046/ j.1525-1594.1999.06218.x 10027883
23. Keller F Bohler J Czok D Zellner D Mertz AKH Individualized drug dosage in patients treated with continuous hemofiltration Kidney Int 1999 72 S29-S31
24. Castela N Taburet AM Carlet J Nitenberg G Wolf M Sollet JP Pharmacokinetics of ceftazidime during continuous infusion in intensive care patients [abstract 11] Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC: American Society for Microbiology 1994 16
25. Jehl F Gallion C Monteil H High-performance liquid chromatography of antibiotics J Chromatogr 1990 531 509-548 2258424
26. Bohler J Donauer J Keller F Pharmacokinetics principles during continuous renal replacement therapy: Drugs and dosage Kidney Int 1999 24-28
27. Benko AS Cappelletty DM Kruse JA Rybak MJ Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections Antimicrob Agents Chemother 1996 40 691-705 163181 8851594
28. Van Dalen R Vree TB Pharmacokinetics of antibiotics in critically ill patients Intensive Care Med 1990 16 Suppl 3 S235-S238 10.1007/BF01709707 2289997
29. Farina A Porra R Cotichini V Doldo A Stability of reconstituted solutions of ceftazidime for injections: An HPLC and CE approach J Pharm Biomed Anal 1999 20 521-530 10.1016/S0731-7085(99)00057-6 10701968
30. Isla A Arzuaga A Maynar J Gascon AR Solinis MA Corral E Pedraz JL Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC J Pharm Biomed Anal 2005 39 996-1005 10.1016/ j.jpba.2005.05.027 16026959
31. Malone RS Fish DN Abraham E Teitelbaum I Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients Antimicrob Agents Chemother 2001 45 3148-3155 90796 11600370 10.1128/ AAC.45.11.3148-3155.2001
32. Isla A Gascon AR Maynar J Arzuaga A Toral D Pedraz JL Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients Clin Ther 2005 27 599-608 10.1016/j.clinthera.2005.05.004 15978309